Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors

US11208422B2 · kind B2 · utility

Assignees

• Bayer Pharma Aktiengesellschaft · DE
• BAYER HEALTHCARE LLC · DE

Inventors

• Martina Delbeck · Essen, DE
• Michael Hahn · Langenfeld, DE
• Thomas Müller · Bonn, DE
• Klemens Lustig · Wuppertal, DE
• Johanna Anlahr · Dortmund, DE
• Karl COLLINS · Düsseldorf, DE
• Janine Nicolai · Essen, DE
• Moritz Beck-Broichsitter · Darmstadt, DE
• Udo Albus · Florstadt, DE
• Doris Gehring · Kelkheim, DE
• Björn Rosenstein · Salmünster, DE
• Hongkai Dang · Xi'an, CN
• Dehe Duan · Xi'an, CN
• Jianfei Yang · Sandy Hook, US
• Denghui Chen · 红钢城街道, CN

Key dates

• Filing date: Jun 7, 2018
• Grant date: Dec 28, 2021
• Expiry date: Jul 1, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.